Mandate

Vinge advises Semantix in connection with the acquisition of Tamarind

June 30, 2010

Vinge has advised Litorina’s portfolio company, Semantix in connection with the acquisition of Tamarind AB, one of Sweden’s leading translation companies providing specialist translation services.

As a result of the acquisition, Semantix has strengthened its position as the leading supplier of specialist language and communication services in the Nordic region. The group has a turnover of more than SEK 300 million and employs approximately 170 people and has more than 6 500 language consultants all over the world.

Semantix’s principal owner is Litorina, a private equity company which focuses on acquiring and developing small and medium sized companies in the Nordic region in co-operation with the management of these companies.

Vinge’s team consisted of responsible partner Johan Winnerblad and associates Joacim Rydergård and Philip Watson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024